[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Clinica Gema Leon\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100557921",false,"NCT06544395","Efficacy of Non-invasive Neuromodulation Treatments for COVID-19 Sequelae","Efficacy of Non-invasive Neuromodulation Treatments for Post-COVID-19 Sequelae in Patients With Musculoskeletal, Respiratory and Neurological Conditions Due to Impaired Taste and Smell.","COVID-19","Inclusion Criteria:\n\n* Patients between the ages of 18 and 60.\n* Patients with a positive diagnosis of COVID-19.\n* Patients with post-COVID-19 sequelae with musculoskeletal, respiratory or neurological symptoms due to taste or smell lasting at least 30 days, with no history of respiratory and\u002For neurological and\u002For musculoskeletal diseases.\n* Patients who signed the informed consent.\n\nExclusion criteria:\n\n* Patients aged before 18 years and after 60 years.\n* Healthy people with no history of neurological, neurological and\u002For respiratory and\u002For musculoskeletal diseases\n* Patients with secondary diseases that could directly affect the systems to be evaluated who were not diagnosed positive for COVID-19.","ALL","18 Years","60 Years",{"count":20,"type":21},104,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to demonstrate the effectiveness of non-invasive Neuromodulation as a therapy in neurological, respiratory and musculoskeletal pathologies derived from the consequences of Covid-19. It will also estimate the impact of non-invasive neuromodulation treatment on the functionality and quality of life of patients with COVID-19 sequelae.The main question it aim to answer is:\n\n\\- Is non-invasive neuromodulation effective as a therapy in neurological, respiratory and musculoskeletal pathologies derived from the consequences of Covid-19.\n\nResearchers will compare non-invasive neuromodulation to a placebo (treatment with the machine turned off).\n\nParticipants will:\n\n* Be evaluated before starting treatment.\n* Be evaluated 3 weeks after.\n* Be evaluated at 5 weeks, or 15 sessions or completion of treatment.\n* Be evaluated 6 weeks after finishing the treatment or 11 weeks after starting treatment.",[27],"Covid-19 Recurrent",[29,30,31],"Covid-19","Non Invasive Neuromodulation","Smell","NOT_YET_RECRUITING","2025-09-17",{"date":35,"type":36},"2025-09-18","ACTUAL",{"date":38,"type":21},"2026-01-01",{"date":40,"type":21},"2026-12-30",{"name":42,"class":43},"Clinica Gema Leon","OTHER",""]